Calcipotriene is a synthetic vitamin D derivative developed to treat psoriasis. It’s available in cream or ointment form. When taken twice a day, this medication may aid in the production of pigment in vitiligo-affected skin areas. After a few months of treatment, results are usually noticeable.


Topical Calcipotriene for Vitiligo

Corticosteroid creams are anti-inflammatory medications that may aid in the recovery of melanocytes or the slowing of vitiligo progression. Because vitiligo necessitates the use of a potent corticosteroid combination, dermatologists closely monitor its use when it’s prescribed. Possible side effects include skin thinning, stretch marks, and acne.

What is Topical Calcipotriene?

Calcipotriene is a vitamin D synthetic derivative that was originally created to treat psoriasis. It comes in the form of a cream or an ointment. This medicine, when used twice daily, may help to increase the creation of pigment in vitiligo-affected areas of the skin. Results are usually visible after a few months of treatment.

After taking the drug, some patients have moderate skin irritation, but further side effects are uncommon. Calcipotriene may be most helpful in the treatment of vitiligo when used in conjunction with other topical medicines, phototherapy, or laser therapies.

Research & Effectiveness of Calciporiene for Vitiligo

The most commonly prescribed treatments for vitiligo are corticosteroids and photochemotherapy, which involves a combination of psoralen and ultraviolet A (PUVA) radiation. These treatments aren’t always effective, and many patients have poor outcomes. Calcipotriene has been demonstrated to be efficacious as a monotherapy and in combination with corticosteroids and phototherapy in adults and children with psoriasis. Because the mechanisms of action for calcipotriene and corticosteroids are different,  anticipated that combining the two drugs would result in increased repigmentation while reducing the negative effects of both.

Twelve vitiligo patients (average age 13.1 years) were instructed to apply topical corticosteroids in the morning and topical calcipotriene at night. With an average of 95 percent repigmentation by body surface area, 83 percent of the 12 patients responded to therapy. Four of the individuals who reacted had previously used topical corticosteroids without success. Repigmentation was present in all of the patients in this group. This treatment was most effective on the eyelids and facial skin.

The medication produced no negative effects on any of the patients. Our findings suggest that topical calcipotriene combined with corticosteroids can repigment vitiligo, even in patients who have previously failed to respond to topical corticosteroids.

Join Our Vitiligo Community

Are you dealing with a recent diagnosis or know someone who has vitiligo? We’re here to help you figure out what works best to manage symptoms and improve overall day-to-day life whether you or someone you love is affected.

Stay up-to-date on the latest news about treatments and managing symptoms. Sign up to get important email updates with relevant information.

This field is for validation purposes and should be left unchanged.